| 1. |
|
|
| 2. |
- Niemi, MEK, et al.
(author)
-
- 2021
-
swepub:Mat__t
|
|
| 3. |
- Kanai, M, et al.
(author)
-
- 2023
-
swepub:Mat__t
|
|
| 4. |
- Murari, A., et al.
(author)
-
A control oriented strategy of disruption prediction to avoid the configuration collapse of tokamak reactors
- 2024
-
In: Nature Communications. - 2041-1723 .- 2041-1723. ; 15:1
-
Journal article (peer-reviewed)abstract
- The objective of thermonuclear fusion consists of producing electricity from the coalescence of light nuclei in high temperature plasmas. The most promising route to fusion envisages the confinement of such plasmas with magnetic fields, whose most studied configuration is the tokamak. Disruptions are catastrophic collapses affecting all tokamak devices and one of the main potential showstoppers on the route to a commercial reactor. In this work we report how, deploying innovative analysis methods on thousands of JET experiments covering the isotopic compositions from hydrogen to full tritium and including the major D-T campaign, the nature of the various forms of collapse is investigated in all phases of the discharges. An original approach to proximity detection has been developed, which allows determining both the probability of and the time interval remaining before an incoming disruption, with adaptive, from scratch, real time compatible techniques. The results indicate that physics based prediction and control tools can be developed, to deploy realistic strategies of disruption avoidance and prevention, meeting the requirements of the next generation of devices.
|
|
| 5. |
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
|
|
| 11. |
|
|
| 12. |
- Abe, O, et al.
(author)
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
- 2005
-
In: The Lancet. - 1474-547X. ; 365:9472, s. 1687-1717
-
Journal article (peer-reviewed)abstract
- Background Quinquennial overviews (1985-2000) of the randomised trials in early breast cancer have assessed the 5-year and 10-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival. Here, we report the 10-year and 15-year effects. Methods Collaborative meta-analyses were undertaken of 194 unconfounded randomised trials of adjuvant chemotherapy or hormonal therapy that began by 1995. Many trials involved CMF (cyclophosphamide, methotrexate, fluorouracil), anthracycline-based combinations such as FAC (fluorouracil, doxombicin, cyclophosphamide) or FEC (fluorouracil, epirubicin, cyclophosphamide), tamoxifen, or ovarian suppression: none involved taxanes, trastuzumab, raloxifene, or modem aromatase inhibitors. Findings Allocation to about 6 months of anthracycline-based polychemotherapy (eg, with FAC or FEC) reduces the annual breast cancer death rate by about 38% (SE 5) for women younger than 50 years of age when diagnosed and by about 20% (SE 4) for those of age 50-69 years when diagnosed, largely irrespective of the use of tamoxifen and of oestrogen receptor (ER) status, nodal status, or other tumour characteristics. Such regimens are significantly (2p=0 . 0001 for recurrence, 2p<0 . 00001 for breast cancer mortality) more effective than CMF chemotherapy. Few women of age 70 years or older entered these chemotherapy trials. For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3), largely irrespective of the use of chemotherapy and of age (<50, 50-69, &GE; 70 years), progesterone receptor status, or other tumour characteristics. 5 years is significantly (2p<0 . 00001 for recurrence, 2p=0 . 01 for breast cancer mortality) more effective than just 1-2 years of tamoxifen. For ER-positive tumours, the annual breast cancer mortality rates are similar during years 0-4 and 5-14, as are the proportional reductions in them by 5 years of tamoxifen, so the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis. These results combine six meta-analyses: anthracycline-based versus no chemotherapy (8000 women); CMF-based versus no chemotherapy (14 000); anthracycline-based versus CMF-based chemotherapy (14 000); about 5 years of tamoxifen versus none (15 000); about 1-2 years of tamoxifen versus none (33 000); and about 5 years versus 1-2 years of tamoxifen (18 000). Finally, allocation to ovarian ablation or suppression (8000 women) also significantly reduces breast cancer mortality, but appears to do so only in the absence of other systemic treatments. For middle-aged women with ER-positive disease (the commonest type of breast cancer), the breast cancer mortality rate throughout the next 15 years would be approximately halved by 6 months of anthracycline-based chemotherapy (with a combination such as FAC or FEC) followed by 5 years of adjuvant tamoxifen. For, if mortality reductions of 38% (age <50 years) and 20% (age 50-69 years) from such chemotherapy were followed by a further reduction of 31% from tamoxifen in the risks that remain, the final mortality reductions would be 57% and 45%, respectively (and, the trial results could well have been somewhat stronger if there had been full compliance with the allocated treatments). Overall survival would be comparably improved, since these treatments have relatively small effects on mortality from the aggregate of all other causes. Interpretation Some of the widely practicable adjuvant drug treatments that were being tested in the 1980s, which substantially reduced 5-year recurrence rates (but had somewhat less effect on 5-year mortality rates), also substantially reduce 15-year mortality rates. Further improvements in long-term survival could well be available from newer drugs, or better use of older drugs.
|
|
| 13. |
|
|
| 14. |
|
|
| 15. |
- Senanayake, Indunil C., et al.
(author)
-
Fungal diversity notes 1611–1716: taxonomic and phylogenetic contributions on fungal genera and species emphasis in south China
- 2023
-
In: Fungal Diversity. - 1560-2745 .- 1878-9129. ; 122, s. 161-403
-
Journal article (peer-reviewed)abstract
- This article is the 15th contribution in the Fungal Diversity Notes series, wherein 115 taxa from three phyla, nine classes, 28 orders, 48 families, and 64 genera are treated. Fungal taxa described and illustrated in the present study include a new family, five new genera, 61 new species, five new combinations, one synonym, one new variety and 31 records on new hosts or new geographical distributions. Ageratinicolaceae fam. nov. is introduced and accommodated in Pleosporales. The new genera introduced in this study are Ageratinicola, Kevinia, Pseudomultiseptospora (Parabambusicolaceae), Marasmiellomycena, and Vizzinia (Porotheleaceae). Newly described species are Abrothallus altoandinus, Ageratinicola kunmingensis, Allocryptovalsa aceris, Allophoma yuccae, Apiospora cannae, A. elliptica, A. pallidesporae, Boeremia wisteriae, Calycina papaeana, Clypeococcum lichenostigmoides, Coniochaeta riskali-shoyakubovii, Cryphonectria kunmingensis, Diaporthe angustiapiculata, D. campylandrae, D. longipapillata, Diatrypella guangdongense, Dothiorella franceschinii, Endocalyx phoenicis, Epicoccum terminosporum, Fulvifomes karaiensis, F. pannaensis, Ganoderma ghatensis, Hysterobrevium baoshanense, Inocybe avellaneorosea, I. lucida, Jahnula oblonga, Kevinia lignicola, Kirschsteiniothelia guangdongensis, Laboulbenia caprina, L. clavulata, L. cobiae, L. cosmodisci, L. nilotica, L. omalii, L. robusta, L. similis, L. stigmatophora, Laccaria rubriporus, Lasiodiplodia morindae, Lyophyllum agnijum, Marasmiellomycena pseudoomphaliiformis, Melomastia beihaiensis, Nemania guangdongensis, Nigrograna thailandica, Nigrospora ficuum, Oxydothis chinensis, O. yunnanensis, Petriella thailandica, Phaeoacremonium chinensis, Phialocephala chinensis, Phytophthora debattistii, Polyplosphaeria nigrospora, Pronectria loweniae, Seriascoma acutispora, Setoseptoria bambusae, Stictis anomianthi, Tarzetta tibetensis, Tarzetta urceolata, Tetraploa obpyriformis, Trichoglossum beninense, and Tricoderma pyrrosiae. We provide an emendation for Urnula ailaoshanensis Agaricus duplocingulatoides var. brevisporus introduced as a new variety based on morphology and phylogeny.
|
|
| 16. |
|
|
| 17. |
|
|
| 18. |
|
|
| 19. |
|
|
| 20. |
|
|
| 21. |
- Lyons, PA, et al.
(author)
-
Genome-wide association study of eosinophilic granulomatosis with polyangiitis reveals genomic loci stratified by ANCA status
- 2019
-
In: Nature communications. - : Springer Science and Business Media LLC. - 2041-1723. ; 10:1, s. 5120-
-
Journal article (peer-reviewed)abstract
- Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disease of unknown cause. 30% of patients have anti-neutrophil cytoplasmic antibodies (ANCA) specific for myeloperoxidase (MPO). Here, we describe a genome-wide association study in 676 EGPA cases and 6809 controls, that identifies 4 EGPA-associated loci through conventional case-control analysis, and 4 additional associations through a conditional false discovery rate approach. Many variants are also associated with asthma and six are associated with eosinophil count in the general population. Through Mendelian randomisation, we show that a primary tendency to eosinophilia contributes to EGPA susceptibility. Stratification by ANCA reveals that EGPA comprises two genetically and clinically distinct syndromes. MPO+ ANCA EGPA is an eosinophilic autoimmune disease sharing certain clinical features and an HLA-DQ association with MPO+ ANCA-associated vasculitis, while ANCA-negative EGPA may instead have a mucosal/barrier dysfunction origin. Four candidate genes are targets of therapies in development, supporting their exploration in EGPA.
|
|
| 22. |
|
|
| 23. |
|
|
| 24. |
|
|
| 25. |
|
|
| 26. |
|
|
| 27. |
- Dierig, A., et al.
(author)
-
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis
- 2023
-
In: Trials. - : BMC. - 1745-6215. ; 24:1
-
Journal article (peer-reviewed)abstract
- Background: Linezolid is an effective, but toxic anti-tuberculosis drug that is currently recommended for the treatment of drug-resistant tuberculosis. Improved oxazolidinones should have a better safety profile, while preserving efficacy. Delpazolid is a novel oxazolidinone developed by LegoChem Biosciences Inc. that has been evaluated up to phase 2a clinical trials. Since oxazolidinone toxicity can occur late in treatment, LegoChem Biosciences Inc. and the PanACEA Consortium designed DECODE to be an innovative dose-ranging study with long-term follow-up for determining the exposure-response and exposure-toxicity relationship of delpazolid to support dose selection for later studies. Delpazolid is administered in combination with bedaquiline, delamanid and moxifloxacin.Methods: Seventy-five participants with drug-sensitive, pulmonary tuberculosis will receive bedaquiline, delamanid and moxifloxacin, and will be randomized to delpazolid dosages of 0 mg, 400 mg, 800 mg, 1200 mg once daily, or 800 mg twice daily, for 16 weeks. The primary efficacy endpoint will be the rate of decline of bacterial load on treatment, measured by MGIT liquid culture time to detection from weekly sputum cultures. The primary safety endpoint will be the proportion of oxazolidinone class toxicities; neuropathy, myelosuppression, or tyramine pressor response. Participants who convert to negative liquid media culture by week 8 will stop treatment after the end of their 16-week course and will be observed for relapse until week 52. Participants who do not convert to negative culture will receive continuation phase treatment with rifampicin and isoniazid to complete a six-month treatment course.Discussion: DECODE is an innovative dose-finding trial, designed to support exposure-response modelling for safe and effective dose selection. The trial design allows assessment of occurrence of late toxicities as observed with linezolid, which is necessary in clinical evaluation of novel oxazolidinones. The primary efficacy endpoint is the change in bacterial load, an endpoint conventionally used in shorter dose-finding trials. Long-term follow-up after shortened treatment is possible through a safety rule excluding slow-and non-responders from potentially poorly performing dosages.
|
|
| 28. |
- Herrick, A. L., et al.
(author)
-
Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study
- 2018
-
In: Annals of the Rheumatic Diseases. - : BMJ. - 0003-4967 .- 1468-2060. ; 77:4, s. 563-570
-
Journal article (peer-reviewed)abstract
- Objectives Our aim was to use the opportunity provided by the European Scleroderma Observational Study to (1) identify and describe those patients with early diffuse cutaneous systemic sclerosis (dcSSc) with progressive skin thickness, and (2) derive prediction models for progression over 12 months, to inform future randomised controlled trials (RCTs). Methods The modified Rodnan skin score (mRSS) was recorded every 3 months in 326 patients. 'Progressors' were defined as those experiencing a 5-unit and 25% increase in mRSS score over 12 months (±3 months). Logistic models were fitted to predict progression and, using receiver operating characteristic (ROC) curves, were compared on the basis of the area under curve (AUC), accuracy and positive predictive value (PPV). Results 66 patients (22.5%) progressed, 227 (77.5%) did not (33 could not have their status assessed due to insufficient data). Progressors had shorter disease duration (median 8.1 vs 12.6 months, P=0.001) and lower mRSS (median 19 vs 21 units, P=0.030) than non-progressors. Skin score was highest, and peaked earliest, in the anti-RNA polymerase III (Pol3+) subgroup (n=50). A first predictive model (including mRSS, duration of skin thickening and their interaction) had an accuracy of 60.9%, AUC of 0.666 and PPV of 33.8%. By adding a variable for Pol3 positivity, the model reached an accuracy of 71%, AUC of 0.711 and PPV of 41%. Conclusions Two prediction models for progressive skin thickening were derived, for use both in clinical practice and for cohort enrichment in RCTs. These models will inform recruitment into the many clinical trials of dcSSc projected for the coming years. Trial registration number NCT02339441. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
|
|
| 29. |
|
|
| 30. |
|
|
| 31. |
|
|
| 32. |
- Laeng, A., et al.
(author)
-
Validation of MIPAS IMK/IAA V5R_O3_224 ozone profiles
- 2014
-
In: Atmospheric Measurement Techniques. - : Copernicus GmbH. - 1867-1381 .- 1867-8548. ; 7:11, s. 3971-3987
-
Journal article (peer-reviewed)abstract
- We present the results of an extensive validation program of the most recent version of ozone vertical profiles retrieved with the IMK/IAA (Institute for Meteorology and Climate Research/Instituto de Astrofisica de Andalucia) MIPAS (Michelson Interferometer for Passive Atmospheric Sounding) research level 2 processor from version 5 spectral level 1 data. The time period covered corresponds to the reduced spectral resolution period of the MIPAS instrument, i.e., January 2005-April 2012. The comparison with satellite instruments includes all post-2005 satellite limb and occultation sensors that have measured the vertical profiles of tropospheric and stratospheric ozone: ACE-FTS, GOMOS, HALOE, HIRDLS, MLS, OSIRIS, POAM, SAGE II, SCIAMACHY, SMILES, and SMR. In addition, balloon-borne MkIV solar occultation measurements and ground-based Umkehr measurements have been included, as well as two nadir sensors: IASI and SBUV. For each reference data set, bias determination and precision assessment are performed. Better agreement with reference instruments than for the previous data version, V5R_O3_220 (Laeng et al., 2014), is found: the known high bias around the ozone vmr (volume mixing ratio) peak is significantly reduced and the vertical resolution at 35 km has been improved. The agreement with limb and solar occultation reference instruments that have a known small bias vs. ozonesondes is within 7% in the lower and middle stratosphere and 5% in the upper troposphere. Around the ozone vmr peak, the agreement with most of the satellite reference instruments is within 5 %; this bias is as low as 3% for ACE-FTS, MLS, OSIRIS, POAM and SBUV.
|
|
| 33. |
|
|
| 34. |
- Lilleker, JB, et al.
(author)
-
The EuroMyositis registry: an international collaborative tool to facilitate myositis research
- 2018
-
In: Annals of the rheumatic diseases. - : BMJ. - 1468-2060 .- 0003-4967. ; 77:1, s. 30-39
-
Journal article (peer-reviewed)abstract
- The EuroMyositis Registry facilitates collaboration across the idiopathic inflammatory myopathy (IIM) research community. This inaugural report examines pooled Registry data.MethodsCross-sectional analysis of IIM cases from 11 countries was performed. Associations between clinical subtypes, extramuscular involvement, environmental exposures and medications were investigated.ResultsOf 3067 IIM cases, 69% were female. The most common IIM subtype was dermatomyositis (DM) (31%). Smoking was more frequent in connective tissue disease overlap cases (45%, OR 1.44, 95% CI 1.09 to 1.90, p=0.012). Smoking was associated with interstitial lung disease (ILD) (OR 1.32, 95% CI 1.06 to 1.65, p=0.013), dysphagia (OR 1.43, 95% CI 1.16 to 1.77, p=0.001), malignancy ever (OR 1.78, 95% CI 1.36 to 2.33, p<0.001) and cardiac involvement (OR 2.40, 95% CI 1.60 to 3.60, p<0.001).Dysphagia occurred in 39% and cardiac involvement in 9%; either occurrence was associated with higher Health Assessment Questionnaire (HAQ) scores (adjusted OR 1.79, 95% CI 1.43 to 2.23, p<0.001). HAQ scores were also higher in inclusion body myositis cases (adjusted OR 3.85, 95% CI 2.52 to 5.90, p<0.001). Malignancy (ever) occurred in 13%, most commonly in DM (20%, OR 2.06, 95% CI 1.65 to 2.57, p<0.001).ILD occurred in 30%, most frequently in antisynthetase syndrome (71%, OR 10.7, 95% CI 8.6 to 13.4, p<0.001). Rash characteristics differed between adult-onset and juvenile-onset DM cases (‘V’ sign: 56% DM vs 16% juvenile-DM, OR 0.16, 95% CI 0.07 to 0.36, p<0.001). Glucocorticoids were used in 98% of cases, methotrexate in 71% and azathioprine in 51%.ConclusionThis large multicentre cohort demonstrates the importance of extramuscular involvement in patients with IIM, its association with smoking and its influence on disease severity. Our findings emphasise that IIM is a multisystem inflammatory disease and will help inform prognosis and clinical management of patients.
|
|
| 35. |
|
|
| 36. |
|
|
| 37. |
|
|
| 38. |
- Aaij, R., et al.
(author)
-
Measurement of antiproton production from antihyperon decays in pHe collisions at √ˆšsNN=110 GeV
- 2023
-
In: European Physical Journal C. - : SPRINGER. - 1434-6044 .- 1434-6052. ; 83
-
Journal article (peer-reviewed)abstract
- The interpretation of cosmic antiproton flux measurements from space-borne experiments is currently limited by the knowledge of the antiproton production cross-section in collisions between primary cosmic rays and the interstellar medium. Using collisions of protons with an energy of 6.5 TeV incident on helium nuclei at rest in the proximity of the interaction region of the LHCb experiment, the ratio of antiprotons originating from antihyperon decays to prompt production is measured for antiproton momenta between 12 and 110 GeV/c. The dominant antihyperon contribution, namely (Lambda) over bar -> (p) over bar pi(+) decays from promptly produced (Lambda) over bar particles, is also exclusively measured. The results complement the measurement of prompt antiproton production obtained from the same data sample. At the energy scale of this measurement, the antihyperon contributions to antiproton production are observed to be significantly larger than predictions of commonly used hadronic production models.
|
|
| 39. |
- Aaij, R., et al.
(author)
-
Measurement of the Λb0 → Λ(1520)Ό+Ό- Differential Branching Fraction
- 2023
-
In: Physical Review Letters. - : American Physical Society. - 0031-9007 .- 1079-7114. ; 131:15
-
Journal article (peer-reviewed)abstract
- The branching fraction of the rare decay Lambda(0 )(b)-> Lambda(1520)mu(+)mu(-) is measured for the first time, in the squared dimuon mass intervals q(2), excluding the J/psi and psi(2S) regions. The data sample analyzed was collected by the LHCb experiment at center-of-mass energies of 7, 8, and 13 TeV, corresponding to a total integrated luminosity of 9 fb(-1). The result in the highest q(2) interval, q(2) > 15.0 GeV2/c(4), where theoretical predictions have the smallest model dependence, agrees with the predictions.
|
|
| 40. |
- Aaij, R., et al.
(author)
-
Model-independent measurement of charm mixing parameters in B → D0(→ K0Sπ+π- )Ό-ΜΌX decays
- 2023
-
In: Physical Review D. - : AMER PHYSICAL SOC. - 2470-0010 .- 2470-0029. ; 108:5
-
Journal article (peer-reviewed)abstract
- A measurement of charm mixing and CP-violating parameters is reported, using B over bar -> D0(-> K0S pi+pi-)x mu- nu over bar mu X decays reconstructed in proton-proton collisions collected by the LHCb experiment during the years 2016 to 2018, corresponding to an integrated luminosity of 5.4 fb-1. The measured mixing and CP-violating parameters are xCP = [4.29 1 1.48(stat) 1 0.26(syst)] x 10-3, yCP = [12.61 1 3.12(stat) 1 0.83(syst)] x 10-3, Ax = [-0.77 1 0.93(stat) 1 0.28(syst)] x 10-3, Ay = [3.01 1 1.92(stat) 1 0.26(syst)] x 10-3. The results are complementary to and consistent with previous measurements. A combination with the recent LHCb analysis of D*+ -> D0(-> K0S pi+ pi-)pi+ decays is reported.
|
|
| 41. |
- Aaij, R., et al.
(author)
-
Search for the rare decays W+ →Ds+ ϒ and Z →D0 ϒ at LHCb
- 2023
-
In: Chinese Physics C. - : Institute of Physics (IOP). - 1674-1137 .- 2058-6132. ; 47:9
-
Journal article (peer-reviewed)abstract
- A search for the rare decays W+ -> D-s(+)gamma and Z -> D-0 gamma and is performed using proton-proton collision data collected by the LHCb experiment at a centre-of-mass energy of 13TeV, corresponding to an integrated luminosity of 2.0fb(-1). No significant signal is observed for either decay mode and upper limits on their branching fractions are set using W+ -> mu(+)nu and Z ->mu(+)mu(-)decays as normalization channels. The upper limits are and at 95% confidence level for W+ -> D-s(+)gamma and Z -> D-0 gamma the and decay modes, respectively. This is the first reported search for Z -> D-0 gamma the decay, while the upper limit on the Z -> D-0 gamma branching fraction improves upon the previous best limit.
|
|
| 42. |
- Aaij, R., et al.
(author)
-
Study of Bc+ meson decays to charmonia plus multihadron final states
- 2023
-
In: Journal of High Energy Physics (JHEP). - : Springer. - 1126-6708 .- 1029-8479. ; :7
-
Journal article (peer-reviewed)abstract
- Four decay modes of the B-c(+) meson into a J/psi meson and multiple charged kaons or pions are studied using proton-proton collision data, collected with the LHCb detector at centre-of-mass energies of 7, 8, and 13TeV and corresponding to an integrated luminosity of 9 fb(-1). The decay B-c(+) -> J/psi K+ K- pi(+)pi(+)pi(-) is observed for the first time, and evidence for the B-c(+) -> J/psi 4 pi(+)3 pi(-) decay is found. The decay B-c(+) -> J/psi 3 pi(+)2 pi(-) is observed and the previous observation of the B-c(+) -> psi(2S)pi(+)pi(+)pi(-) decay is confirmed using the psi(2S) -> J/psi pi(+)pi(-) decay mode. Ratios of the branching fractions of these four B-c(+) decay channels are measured.
|
|
| 43. |
- Aaij, R., et al.
(author)
-
Study of charmonium decays to KS0Kπ in the B → (KS0Kπ)K channels
- 2023
-
In: Physical Review D. - : American Physical Society. - 2470-0010 .- 2470-0029. ; 108:3
-
Journal article (peer-reviewed)abstract
- A study of the B+ -> (KSK+)-K-0 K-pi(+) and B+ -> (KSK+K+)-K-0 pi(-) decays is performed using proton-proton collisions at center-of-mass energies of 7, 8 and 13 TeV at the LHCb experiment. The (KSK)-K-0 pi invariant mass spectra from both decay modes reveal a rich content of charmonium resonances. New precise measurements of the eta(c) and eta(c)(2S) resonance parameters are performed and branching fraction measurements are obtained for B+ decays to eta(c), J/psi, eta(c)(2S) and chi(c1) resonances. In particular, the first observation and branching fraction measurement of B+ -> chi K-c0(0)pi(+) is reported as well as first measurements of the B+ -> (KK+K-)-K-0 pi(+) and B+ -> (KK+K+)-K-0 pi(-) branching fractions. Dalitz plot analyses of eta(c) -> (KSK)-K-0 pi and eta(c)(2S) -> (KSK)-K-0 pi decays are performed. A new measurement of the amplitude and phase of the K pi S-wave as functions of the K pi mass is performed, together with measurements of the K-0*(1430), K-0*(1950) and a(0)(1700) parameters. Finally, the branching fractions of chi(c1) decays to K* resonances are also measured.
|
|
| 44. |
- Aaij, R., et al.
(author)
-
Study of the B- → Λc+(Λ)over-barc-K- decay
- 2023
-
In: Physical Review D. - : American Physical Society. - 2470-0010 .- 2470-0029. ; 108:1
-
Journal article (peer-reviewed)abstract
- The decay B- -> Lambda(+)(c)(Lambda) over bar K--(c)- is studied in proton-proton collisions at a center-of-mass energy of root s = 13 TeV using data corresponding to an integrated luminosity of 5 fb(-1) collected by the LHCb experiment. In the Lambda K-+(c)- system, the Xi(c)(2930)(0) state observed at the BABAR and Belle experiments is resolved into two narrower states, Xi(c)(2923)(0) and Xi(c)(2939)(0), whose masses and widths are measured to be m(Xi(c)(2930)(0) = 2924.5 +/- 0.4 +/- 1.1 Mev, m Xi(c)(2930)(0)) = 2938.5 +/- 0.9 +/- 2.3 Mev, Gamma(Xi(c)(2930)(0)) = 4.8 +/- 0.9 +/- 1.5 MeV, Gamma(Xi(c)(2930)(0) - 11.0 +/- 1.9 +/- 7.5 MeV, where the first uncertainties are statistical and the second systematic. The results are consistent with a previous LHCb measurement using a prompt Lambda K-+(c)- sample. Evidence of a new Xi(c)(2930)(0) state is found with a local significance of 3.8 sigma, whose mass and width are measured to be 2881.8 +/- 3.1 +/- 8.5 MeV and 12.4 +/- 5.3 +/- 5.8 MeV, respectively. In addition, evidence of a new decay mode Xi(c)(2930)(0) -> Lambda K-+(c) is found with a significance of 3.7 sigma. The relative branching fraction of B- -> Lambda(+)(c)(Lambda) over bar K--(c)- with respect to the B- -> D+D-K- decay is measured to be 2.36 +/- 0.11 +/- 0.22 +/- 0.25, where the first uncertainty is statistical, the second systematic and the third originates from the branching fractions of charm hadron decays.
|
|
| 45. |
|
|
| 46. |
|
|
| 47. |
- Apel, Maria, et al.
(author)
-
Variants in RUNX3 Contribute to Susceptibility to Psoriatic Arthritis, Exhibiting Further Common Ground With Ankylosing Spondylitis
- 2013
-
In: Arthritis and Rheumatism. - : Wiley. - 0004-3591 .- 1529-0131. ; 65:5, s. 1224-1231
-
Journal article (peer-reviewed)abstract
- Objective Psoriatic arthritis (PsA) is a common inflammatory joint disease distinct from other chronic arthritides and frequently accompanied by psoriasis vulgaris. In a first genome-wide association study (GWAS), we were able to identify several genetic risk factors. However, even combined with previously identified factors, the genetic contribution to disease was not fully explained. Therefore, we undertook this study to investigate further 17 loci from our GWAS that did not reach genome-wide significance levels of association in the initial analysis. Methods Twenty-one of 22 single-nucleotide polymorphisms were successfully genotyped in independent cohorts of 1,398 PsA patients and 6,389 controls and in a group of 964 German patients with psoriasis vulgaris. Results Association with a RUNX3 variant, rs4649038, was replicated in independent patients and controls and resulted in a combined P value of 1.40 x 108 by Cochran-Mantel-Haenszel test and an odds ratio (OR) of 1.24 (95% confidence interval [95% CI] 1.151.33). Further analyses based on linkage disequilibrium (LD) at RUNX3 refined the most significant association to an LD block located in the first intron of one isoform. Weaker evidence for association was detected in German patients with psoriasis vulgaris (P = 5.89 x 102; OR 1.13 [95% CI 1.001.28]), indicating a role in the skin manifestations of psoriasis. Conclusion Our analyses identified variants in RUNX3 as susceptibility factors for PsA. RUNX3 has already been implicated in susceptibility to ankylosing spondylitis, another spondyloarthritis, although its risk allele is independent from the one for PsA. RUNX-3 is involved in CD8+ T lymphocyte differentiation and is therefore a good candidate for involvement in PsA and psoriasis vulgaris as T cellmediated diseases.
|
|
| 48. |
- Azevedo, Flavio, et al.
(author)
-
Social and moral psychology of COVID-19 across 69 countries
- 2023
-
In: Scientific Data. - : NATURE PORTFOLIO. - 2052-4463. ; 10:1
-
Journal article (peer-reviewed)abstract
- The COVID-19 pandemic has affected all domains of human life, including the economic and social fabric of societies. One of the central strategies for managing public health throughout the pandemic has been through persuasive messaging and collective behaviour change. To help scholars better understand the social and moral psychology behind public health behaviour, we present a dataset comprising of 51,404 individuals from 69 countries. This dataset was collected for the International Collaboration on Social & Moral Psychology of COVID-19 project (ICSMP COVID-19). This social science survey invited participants around the world to complete a series of moral and psychological measures and public health attitudes about COVID-19 during an early phase of the COVID-19 pandemic (between April and June 2020). The survey included seven broad categories of questions: COVID-19 beliefs and compliance behaviours; identity and social attitudes; ideology; health and well-being; moral beliefs and motivation; personality traits; and demographic variables. We report both raw and cleaned data, along with all survey materials, data visualisations, and psychometric evaluations of key variables.
|
|
| 49. |
|
|
| 50. |
- Bowes, John, et al.
(author)
-
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis : evidence for a further PsA-specific risk locus
- 2015
-
In: Annals of the Rheumatic Diseases. - : BMJ. - 0003-4967 .- 1468-2060. ; 74:10, s. 1882-1885
-
Journal article (peer-reviewed)abstract
- Objectives Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis; it has a higher estimated genetic component than psoriasis alone, however most genetic susceptibility loci identified for PsA to date are also shared with psoriasis. Here we attempt to validate novel single nucleotide polymorphisms selected from our recent PsA Immunochip study and determine specificity to PsA. Methods A total of 15 single nucleotide polymorphisms were selected (P-Immunochip <1x10(-4)) for validation genotyping in 1177 cases and 2155 controls using TaqMan. Meta-analysis of Immunochip and validation data sets consisted of 3139 PsA cases and 11 078 controls. Novel PsA susceptibility loci were compared with data from two large psoriasis studies (WTCCC2 and Immunochip) to determine PsA specificity. Results We found genome-wide significant association to rs2476601, mapping to PTPN22 (p=1.49x10(-9), OR=1.32), but no evidence for association in the psoriasis cohort (p=0.34) and the effect estimates were significantly different between PsA and psoriasis (p=3.2x10(-4)). Additionally, we found genome-wide significant association to the previously reported psoriasis risk loci; NOS2 (rs4795067, p=5.27x10(-9)). Conclusions For the first time, we report genome-wide significant association of PTPN22 (rs2476601) to PsA susceptibility, but no evidence for association to psoriasis.
|
|
